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difficulties. RESULTS: Three methods were identified for mitigating the 
challenges of simulation modeling. First, the implementation of the model can 
be simplified by minimizing the dependence on random number draws 
wherever possible. For example, a single, cumulative probability of treatment 
discontinuation can replace a series of separate, time-dependent discontinuation 
probabilities. Second, the transparency and efficiency of the computations can 
be improved by anticipating all the random draws required to determine a 
patient’s experiences and organizing the calculations so that a sufficient batch of 
random numbers can be generated at the beginning of the patient’s sojourn 
through the model. Lastly, and perhaps most importantly, the face validity of the 
model can be ensured through the visual representation of sample patient 
experiences that highlight the ability of the model to more accurately represent 
reality. CONCLUSIONS: Our modeling experiences have demonstrated that 
meaningful steps can be taken to capitalize on the flexibility of patient-level 
simulation modeling while maintaining critical aspects of transparency and 
efficiency.  
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OBJECTIVES: To classify each of the stakeholders in National Essential Drug 
System(NEDS) in China by three major attributes: power, legitimacy and urgency. 
To predict the outcome of the whole system by using the Stakeholder Impact 
Index (SII). To evaluate the current performances of each main stakeholder and 
identify definitive stakeholders and dangerous stakeholders. To develope a 
circular model for NEDS based on indexes collected by Delphi method. 
METHODS: A circular model has been developed to map all major stakeholders 
in the NEDS using quantitative data collected by Delphi method involving 36 
experts with experience in implementation of essential drug policy were 
interviewed. RESULTS: The central government in the circular model for 
essential drug system was a dominant stakeholder of the whole stakeholder 
system. The provincial governments were definitive stakeholders while local 
governments and medical institutions were dependent stakeholders. 
Furthermore, media and drug stores were dormant stakeholders, pharmaceutical 
manufacturers and distribution enterprises were dangerous stakeholders. 
Patients, community residents and medical insurance programs were 
discretionary stakeholders. The Stakeholder Impact Index for the NEDS was 
positive (SIIproj* = 2.72). CONCLUSIONS: Our finding indicates that the overall 
anticipation of national essential drug policy is optimistic. Provincial 
governments, which should be in the position of leading the implementation of 
essential drug policy, need to be given more autonomy and the constrcution of 
an experience exchanging platform within provinces in the form of annual 
symposium, seasonal meeting, learning class or video conferences may 
accelerate the pace of implementation of national essential drug policy. 
Pharmaceutical manufacturers and distribution enterprises should be taken 
more seriously care of in order to make sure they follow the policy rather than 
devastate it for their own benefits. Constructing a fare, balanced and self-
sustained bidding platform may be the key solution for preventing such a 
phenomenon.  
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OBJECTIVES: To modify the traditional framework for conducting ENBS, which is 
not compatible with drug development in the pharmaceutical industry. 
METHODS: We modify the traditional framework for conducting ENBS and make 
it more relevant to the pharmaceutical industry. Traditional approaches to ENBS 
value trials according to the expected benefits to society and the price of the 
intervention is assumed to be fixed. We use expected profit forecasts to value 
trials and assume that the price of the drug is variable and conditional on the 
trial outcomes. Value Based Pricing (VBP) is a pricing strategy where drug prices 
are generated in a CE model according to the cost-per-QALY threshold. We use 
this criterion to determine price. We assume that there is a threshold price 
below which the company would not market the new intervention and would 
receive zero profits. The expected price varies as different trial characteristics 
are simulated. A case study in which the sample size and trial duration are 
varied in a Phase III trial for Systemic Lupus Erythematosus (SLE). For each trial 
design we sampled 1000 trial outcomes. VBP was estimated for each simulated 
trial using a SLE CE model. Expected profit of the trial is estimated by averaging 
across all trial samples. ENBS is calculated as the expected profits minus the 
costs of the trial. RESULTS: A clinical trial with longer follow-up generated 
greater ENBS than a shorter trial with larger sample size. There is large variation 
in the expected profits for the clinical trials. CONCLUSIONS: ENBS can be 
adapted to value clinical trials in the pharmaceutical industry to optimise the 
expected profits. However, the analyses can be very time-consuming to run for 
complex CE models.  
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Uncertainty in parameters is present in many risk assessment and decision 
making problems and leads to uncertainty in model predictions. Therefore an 
analysis of the degree of uncertainty around the model inputs is often needed. 
Importance analysis involves use of quantitative methods aiming at identifying 
the contribution of uncertain input model parameters to output uncertainty. 
Expected value of partial perfect information (EVPPI) measure is a current gold- 
standard technique for measuring parameters importance in health economics 
models. The current standard approach of estimating EVPPI through performing 
double Monte Carlo simulation (MCS) can be associated with a long run time. 
OBJECTIVES: To investigate different importance analysis techniques with an 
aim to find alternative technique with shorter run time that will identify 
parameters with greatest contribution to uncertainty in model output. 
METHODS: A health economics model was updated and served as a tool to 
implement various importance analysis techniques. Twelve alternative 
techniques were applied: rank correlation analysis, contribution to variance 
analysis, mutual information analysis, dominance analysis, regression analysis, 
analysis of elasticity, ANCOVA, maximum separation distances analysis, 
sequential bifurcation, double MCS EVPPI, EVPPI-quadrature and EVPPI- single 
MCS method. RESULTS: Among all these techniques, the dominance analysis 
resulted with the closest correlated calibrated scores when compared with EVPPI 
calibrated scores. CONCLUSIONS: Performing a dominance analysis as a 
screening method to identify subgroup of parameters as candidates for being 
most important parameters and subsequently only performing EVPPI analysis on 
the selected will reduce the overall run time.  
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OBJECTIVES: A study of recently published health economic models found that 
face/internal validation, while recommended by ISPOR guidelines, was reported 
in less than half and third party validation (performed by individuals outside of 
the model building process with no stake in model results) was utilized in less 
than ¼ of published models. This study follows up on those primary results to 
investigate whether the rates of face, internal, and third-party model validation 
varies by type of publication, type of model, and geographic region. METHODS: 
The published models (n=136) from the primary study were categorized by type 
of publication (HEOR or non-HEOR), by type of model (cost-effectiveness analysis, 
cost-utility analysis, budget impact analysis, or other), and by geographic region 
(North America, Europe, or rest of the world). The rate of face and internal 
validation for each category was aggregated and compared. The analysis was 
also supplemented with additional published modeling studies for categories 
with limited numbers of studies from the primary analysis. The primary study’s 
methodology for determining model validation was followed for the 
supplemental models. RESULTS: The percentage of models that were either face/ 
internally validated varied with respect to the region, publication type, or type of 
model. Among the three different categories analyzed, each failed to conduct 
model validation at greater than a 50% rate. More specifically, the universally 
lowest method of validation by authors in all categories surveyed was through 
the use of a third party. CONCLUSIONS: Whether models were published in 
different types of journals, from a variety of countries, or varied by type of 
model, the rate of validation was similarly low throughout the published 
scientific literature. While the rate varies among the model characteristics 
analyzed, the results suggest that, regardless of model characteristic, ISPOR 
validation guidelines are not widely followed.  
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OBJECTIVES: The purpose of the study was to compare pharmacy-based  
and diagnosis-based indexes in predicting the total health care expenditure  
in current year and next year for the adult asthmatic population. METHODS: 
Data from panel 11 involving asthmatic patients aged 18 years or more were 
selected from the 2006-2007 Medical Expenditure Panel Survey (MEPS)  
The diagnosis-based index was coded according to the D’Hoore version of  
the Charlson comorbidity index, and the pharmacy-based index was defined 
using Chronic Disease Score-1 (CDS-1). The performance of both indexes  
was evaluated for the current year and next year. Additional variables included 
in the multivariable model were demographic characteristics, the number  
of prescribed medications and refills (NPM), and the number of emergency visits. 
RESULTS: The mean age (± Standard Deviation) in the study was 47.48±0.87 years 
and the mean total health expenditure was $8,285±500. Most of the selected 
patients were female (68%) and the vast majority of them were white (82%). The 
CDS-1 (adj R2 for current year=0.2483, and adj R2 for next year = 0.2469) 
performed better than D’Hoore (adj R2 for current year=0.1286, and adj R2  
for next year = 0.1271) when they were added individually. The best predictive 
model included age, sex, NPM, and either D’Hoore (adj R2 for current year = 
0.4334 and adj R2 for next year =0.4294) or CDS-1 (adj R2 for current year =0.4346 
and adj R2 for next year =0.4304). CONCLUSIONS: The best predictive model  
for the current and the prospective year was the model that includes 
demographics, number of prescriptions, and either pharmacy-based or 
diagnosis-based indexes  
